Gene editing, human dignity and Christian responsibility
Gene editing has moved from science fiction into serious laboratory work. Tools such as CRISPR can alter DNA with remarkable precision, raising hopes for treatments for inherited conditions while also forcing difficult questions about safety, consent, disability, inequality and the limits of human authority.
For Christians, the issue cannot be reduced to choosing between science and Scripture. A responsible conversation asks what kind of healing is being pursued, who benefits, who carries the risks and how a view of humanity made in God’s image should shape innovation. We spoke with Daniel Mokoena, a Christian biotech entrepreneur whose work connects medical research, business leadership and public ethics.
From laboratory promise to moral responsibility
“Gene editing is a tool, not a moral argument,” Mokoena says. “A scalpel can repair an injury or cause harm. The same is true of a molecular technology. We have to examine the purpose, the safeguards and the social consequences.”
His company develops platforms for somatic gene therapies, which modify cells in an existing patient without changing the DNA passed to future generations. This distinction matters. Somatic treatment may offer a route for addressing conditions such as sickle-cell disease or certain cancers. Germline editing, by contrast, affects eggs, sperm or embryos and could influence descendants who cannot consent.
The Christian concern is therefore not an automatic rejection of biotechnology. It is a call for wisdom. Healing disease can express love of neighbour, while the pursuit of designer traits, commercial advantage or genetic control may reveal a very different ambition.
What does healing mean?
“I begin with the patient rather than the technique,” Mokoena explains. “If a child has a severe genetic disorder, families may reasonably hope that research will reduce suffering. Their hope deserves compassion, not a lecture.”
At the same time, he resists language suggesting that every difference must be corrected. People living with disability have often experienced exclusion because society was designed without them in mind. A gene-editing programme should never imply that a person’s value depends on meeting a biological standard.
This is where Christian anthropology adds depth to medical ethics. Human dignity is received, not engineered. A person is more than a genome, a diagnosis or a predicted level of productivity. That conviction should influence clinical decisions, research communication and the way companies describe potential benefits.
Consent across generations
In ordinary medical research, informed consent is already demanding. Researchers must explain uncertainty, side effects and alternatives in language participants can understand. Germline editing makes the question harder because future generations would live with the consequences without having chosen them.
Mokoena says his company treats consent as a continuing relationship rather than a signature on a form. “People need time, independent advice and the freedom to say no. A desperate family should not feel that participation is the only responsible choice.”
Australian regulation reflects these concerns. Research involving human embryos, reproductive technologies and genetic modification operates within a tightly controlled legal and ethical environment, with oversight involving bodies such as the National Health and Medical Research Council and the Office of the Gene Technology Regulator. The fact that a technique is technically possible does not make it ready for clinical use.
The Australian context
Australia’s research economy is concentrated around universities, hospitals and biotechnology hubs in Sydney, Melbourne, Brisbane and Adelaide. That creates valuable collaboration, but it can also make access uneven. A promising therapy developed near Parkville may remain distant from families in regional Queensland, the Northern Territory or rural Western Australia.
“There is a danger of building a first-class treatment system that only works for people who can travel, pay privately or navigate specialist networks,” Mokoena says. “Justice has to be considered before the product reaches the market.”
Indigenous communities also deserve meaningful participation in decisions affecting genetic research. Consultation cannot be a late-stage public-relations exercise. It should involve respect for community authority, cultural perspectives, data governance and the history of medical exploitation. Australia’s biotech sector must earn trust patiently, especially when research involves biological samples or family genetic information.
Innovation, profit and the common good
A biotech company needs investment, intellectual property and a viable pathway to manufacturing. Those commercial realities do not automatically make the work unethical. Revenue can support expensive trials and help therapies reach patients. The ethical question is whether profit becomes the only measure of success.
Mokoena describes three tests used in his organisation: scientific credibility, patient benefit and social fairness. A project can fail even when its laboratory results look impressive if its risks are poorly understood or its price would make access unrealistic.
The same discipline applies to public communication. Gene editing is frequently presented through dramatic headlines, but patients need honest distinctions between an early laboratory result, an animal study and an approved treatment. Christian leaders, teachers and scientists can help congregations resist both fearmongering and technological hype.
For students considering these questions, resources that connect wonder, evidence and faith can be useful. A discussion of African skywatchers, ancient wisdom and modern astronomy offers a helpful example of how Christian students can engage scientific discovery without treating curiosity as a threat: Christian students.
How churches can join the conversation
Churches do not need to become genetics laboratories to contribute wisely. They can create space for people affected by inherited disease, invite scientists to explain their work, and teach biblical themes such as stewardship, neighbour-love, justice, humility and care for the vulnerable.
Pastoral support is especially important when families face reproductive decisions or receive a frightening diagnosis. A church should avoid simplistic promises that faith will produce a particular medical outcome. Prayer, practical care and careful listening can stand alongside appropriate medical expertise. Some families may also value night prayer resources as they seek language for fear, hope and endurance.
Young people deserve an environment where asking questions is welcomed. A Year 12 student in Melbourne, a medical trainee in Perth or a church youth group in Newcastle may encounter gene editing through social media before hearing a thoughtful Christian perspective. Honest discussion can show that faith is capable of moral reasoning, scientific literacy and intellectual humility.
A practical framework for discernment
Mokoena offers a simple set of questions for evaluating new genetic technologies. First, what problem is being addressed, and how serious is the burden? Second, is the intervention somatic or germline? Third, what is known about off-target effects, long-term monitoring and reversibility? Fourth, who has been included in the research, and who may be excluded from its benefits?
He adds questions that are less technical but equally important: Does the language honour people living with disability? Are families being pressured by commercial interests? Could the technology deepen existing inequalities? Are Indigenous and local communities participating in decisions about data and biological material? What accountability exists if a company’s predictions prove wrong?
| Question | Responsible direction | Warning sign |
|---|---|---|
| What is the purpose? | Treating serious disease and reducing suffering | Enhancing status, appearance or commercial advantage |
| Which cells are changed? | Carefully monitored somatic cells | Heritable germline changes without broad consent |
| Who benefits? | Patients across communities and income levels | Access limited to wealthy early adopters |
| How is consent handled? | Clear information, time and independent advice | Pressure, hype or vague promises |
| What does dignity mean? | Valuing every person beyond biology | Treating disability as a defect that erases worth |
The Christian biotech entrepreneur’s central message is measured rather than dramatic: “We should pursue excellent science with moral patience. The goal is not to prove that Christians are pro-technology or anti-technology. The goal is to seek faithful, truthful and compassionate action.”
Gene editing will continue to develop, and public policy will need to keep pace with the science. Churches, schools, researchers, investors and families all have a role in that work. Support informed dialogue in your congregation or classroom, invite qualified voices into the discussion, and encourage biotechnology that protects human dignity while seeking genuine healing.